Narcolepsy with cataplexy is a neurological sleep disorder, which is believed to arise from the autoimmune destruction of hypocretin-producing neurons. The purinergic receptor P2Y is associated with narcolepsy in genome-wide association studies, and P2RY11 sequencing has further revealed eight rare missense mutations associated with the disease. Some of these mutations alter the signaling properties of P2Y, but for some, no functional effects have been discovered so far.
This study examined the surface expression of the eight narcolepsy-associated P2Y mutations using an in vitro surface expression assay.
The assay showed excellent discrimination between cells transfected with tagged wild type and the untagged P2Y receptor, proving complete specificity towards the 3HA-N-tag used for the assay. Our results show a decreased surface expression of the R307W P2Y mutant and a surface expression similar to wild type for the other seven mutants.
Based on the present findings, alteration in surface expression is not likely to play a role in how P2Y influences narcolepsy pathogenesis. This is important because intact surface expression increases the usefulness of P2Y as a future drug target.
Related Posts
A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases.
January 31, 2020
Covid-19: Vaccine Shows Immune Response at All Doses, Phase III Trial to Launch July 27
July 16, 2020
Advertisement
Meeting Coverage
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.